Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Compound ipratropium bromide solution for inhalation (COBIT)

This product is suitable for patients who need a combination of multiple bronchodilators to treat reversible bronchospasm related to airway obstructive diseases. More role
App download minus 10 yuan
Common name:
Compound ipratropium bromide solution for inhalation
Product No.:
B14200071305
Approval No.:
H20150173 (original h20120544) (inquired by the State Drug Administration)
Jianke price:
¥80.00
Product specification:
2.5ml * 10 pieces
Manufacturer:
Laboratoire unither (France)
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Compound ipratropium bromide solution for inhalation (COBIT)
Main raw materials This product is a compound preparation. Its components are: each vial (2.5ml) of inhalation solution contains 0.500mg of ipratropium bromide (equivalent to 0.522mg of ipratropium bromide Monohydrate) and 3.000mg of salbutamol sulfate (equivalent to 2.5mg of salbutamol base).
Main role This product is suitable for patients who need a combination of multiple bronchodilators to treat reversible bronchospasm related to airway obstructive diseases.
Product specification 2.5ml * 10 pieces
Usage and dosage This product can be administered through a suitable atomizer or intermittent positive pressure ventilator. The following recommended doses are for adults (including the elderly) and adolescents over the age of 12: Acute attack: In most cases, one vial of therapeutic dose can alleviate symptoms. For serious cases, when one vial of therapeutic dose can not alleviate symptoms, two vials of drugs can be used for treatment, but the patient must see a doctor or go to the nearest hospital as soon as possible. Maintenance treatment period: Use 1 vial 3 ~ 4 times a day. Special groups: Due to the lack of medication data for children, this product is not suitable for children. No study has been carried out on Kebite in patients with liver and renal insufficiency, so such patients should use this product with caution. Anti inflammatory drugs should be considered when treating asthma. If increasing the inhalation amount of this product can not improve the acute or rapidly deteriorating dyspnea, it is recommended that the patient consult a doctor or go to a nearby hospital immediately. instructions: This product can only be inhaled through a suitable atomization device, and can not be administered orally or by other means. This product does not need to be diluted when atomized. 1. Prepare the atomizer according to the manufacturer's requirements or under the guidance of a doctor to add atomized inhalation liquid. 2. Open the tin foil bag and tear a vial from the drug strip. 3. Twist the top and open the vial. 4. Squeeze the liquid medicine in the vial into the medicine dish of the atomizer. 5. Install the atomizer and apply the medicine according to the instructions. 6. According to the manufacturer's instructions, after the atomizer is used, discard the remaining liquid medicine in the atomizer dish and clean the atomizer for next use. Since this product does not contain preservatives, in order to avoid bacterial contamination of the drug, it is very important to use it immediately after the drug bottle is opened. It is very important to use a new small drug bottle during each inhalation treatment. The opened or damaged drug bottles should be discarded and should not be used. In particular, users should be reminded not to mix this product with other drugs in the same atomizer!
manufacturing enterprise Laboratoire unither (France)
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Special personnel are assigned to manage and ensure product inventory.

[drug name] Compound ipratropium bromide solution for inhalation (COBIT)

[common name] Compound ipratropium bromide solution for inhalation

[specification and model] 2.5ml * 10 pieces

[manufacturer] Laboratoire unither (France)

[drug type] Western medicine

[approval No.] H20150173 (original h20120544)

[validity period] 36 months

[functional indications] This product is suitable for patients who need a combination of multiple bronchodilators to treat reversible bronchospasm related to airway obstructive diseases.

[usage and dosage] This product can be administered through a suitable atomizer or intermittent positive pressure ventilator. The following recommended doses are for adults (including the elderly) and adolescents over the age of 12: Acute attack: In most cases, one vial of therapeutic dose can alleviate symptoms. For serious cases, when one vial of therapeutic dose can not alleviate symptoms, two vials of drugs can be used for treatment, but the patient must see a doctor or go to the nearest hospital as soon as possible. Maintenance treatment period: Use 1 vial 3 ~ 4 times a day. Special groups: Due to the lack of medication data for children, this product is not suitable for children. No study has been carried out on Kebite in patients with liver and renal insufficiency, so such patients should use this product with caution. Anti inflammatory drugs should be considered when treating asthma. If increasing the inhalation amount of this product can not improve the acute or rapidly deteriorating dyspnea, it is recommended that the patient consult a doctor or go to a nearby hospital immediately. instructions: This product can only be inhaled through a suitable atomization device, and can not be administered orally or by other means. This product does not need to be diluted when atomized. 1. Prepare the atomizer according to the manufacturer's requirements or under the guidance of a doctor to add atomized inhalation liquid. 2. Open the tin foil bag and tear a vial from the drug strip. 3. Twist the top and open the vial. 4. Squeeze the liquid medicine in the vial into the medicine dish of the atomizer. 5. Install the atomizer and apply the medicine according to the instructions. 6. According to the manufacturer's instructions, after the atomizer is used, discard the remaining liquid medicine in the atomizer dish and clean the atomizer for next use. Since this product does not contain preservatives, in order to avoid bacterial contamination of the drug, it is very important to use it immediately after the drug bottle is opened. It is very important to use a new small drug bottle for each inhalation treatment. Medicine bottles that have been opened or damaged should be discarded and should not be used. In particular, users should be reminded not to mix this product with other drugs in the same atomizer!

[adverse reactions] Many of the listed adverse reactions are related to anticholinergic drugs and β 2 - related to the characteristics of sympathetic drugs. Like other inhalation treatments, this product can have local irritation symptoms. Adverse drug reactions are defined according to clinical trials and pharmacovigilance data after the drug is approved for use. The most common adverse reactions reported in clinical trials include headache, throat irritation, cough, dry mouth, gastrointestinal motility disorders (including constipation, diarrhea and vomiting), nausea and dizziness. (see instructions for details)

[precautions] hypersensitivity After using this product, rapid hypersensitivity may occur, which is characterized by rubella, angioedema, rash, bronchospasm and oropharyngeal edema in very few cases. Paradoxical bronchospasm Like other inhaled drugs, this product may cause life-threatening contradictory bronchospasm. In case of contradictory bronchospasm, the use of this product should be stopped immediately and treated with alternative therapy. Ocular complications When atomized ipratropium bromide alone or with adrenaline β When 2-receptor agonists are used in combination, there are individual cases of ocular complications (such as mydriasis, increased intraocular pressure, narrow-angle glaucoma and eye pain) when the atomized liquid enters and contacts the patient's eyes. Eye pain or eye discomfort, blurred vision, visual halo or color image related to red eye caused by conjunctival congestion, and corneal edema may be the signs of acute narrow-angle glaucoma. If some of the above symptoms occur, you should first use mydriasis drugs and seek medical advice immediately. Patients should use this product correctly under guidance. Care should be taken to prevent liquid medicine or mist from entering the eyes. Especially remind patients with glaucoma tendency to pay attention to eye protection. It is recommended that the patient inhale the atomizing solution (UDV) of this product through the nozzle. If the device is not available, a suitable atomizing mask can be used. Systemic effect When the following diseases occur, especially when the dosage exceeds the recommended dose, the product should be carefully weighed after the risk and benefit are taken: the diabetes that has not yet been effectively controlled, recent myocardial infarction, severe organic cardiovascular disease, hyperthyroidism, chromaffin cell tumor, high risk of narrow angle glaucoma, hypertrophy of the prostate or bladder neck obstruction. Cardiovascular effect Sympathetic drugs, including this product, may have cardiovascular effects. Post marketing data and published literature show that there is very little myocardial ischemia caused by salbutamol. Patients with potentially serious heart diseases (such as ischemic heart disease, arrhythmia or severe heart failure) should use salbutamol to treat respiratory diseases. If they have symptoms of chest pain or deterioration of other heart diseases, they should seek medical advice immediately. Since dyspnea and chest pain may originate from the respiratory tract or the heart, special attention should be paid to evaluating these symptoms. Hypokalemia

[taboo] This product is forbidden for patients with hypertrophic obstructive cardiomyopathy and tachyarrhythmia. This product is also prohibited for patients who are known to be allergic to atropine, its derivatives, or any other components of this product.

[listing Permit Holder] Laboratoire unither (France)

[packaging unit] box

[main ingredients] This product is a compound preparation. Its components are: each vial (2.5ml) of inhalation solution contains 0.500mg of ipratropium bromide (equivalent to 0.522mg of ipratropium bromide Monohydrate) and 3.000mg of salbutamol sulfate (equivalent to 2.5mg of salbutamol base).

[character] Colorless or almost colorless clear liquid.

[applicable population] Adult, elderly

[medication for pregnant and lactating women] In human pregnancy, the safety of this product has not been determined, and it should be used routinely and carefully during pregnancy, especially in the first three months. The inhibitory effect of this product on uterine contraction should be considered. Salbutamol sulfate and ipratropium bromide can be excreted from milk, and the impact on newborns is unknown. Although non fat soluble tetravalent alkali can enter milk, ipratropium bromide is unlikely to enter infants to a large extent However, since many drugs are excreted from breast milk, special caution should be taken for lactating women.

[medication for children] There is no clinical experience of using this product in children under 12 years old.

[medication for elderly patients] Not yet clear.

[storage] Keep away from light below 25 ℃

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Compound ipratropium bromide solution for inhalation (COBIT)

    ¥80.00

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!